Epigenomics AG Successfully Optimized Assay Procedure for Cancer Screening Tests

Epigenomics AG (Frankfurt, Prime Standard: ECX) has reached a milestone in completing the work on an optimized assay procedure for its blood-based cancer screening tests. The most advanced of these, the colorectal cancer screening test, is now ready for its planned reference laboratory transfer.

MORE ON THIS TOPIC